Trial Profile
An open label, randomized, parallel-group study assessing the effect of Cytochrome P450 (Cyp) 3A4 inhibition on the pharmacokinetics and safety of Quizartinib and its active metabolite, Ac886
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2018
Price :
$35
*
At a glance
- Drugs Quizartinib (Primary) ; Fluconazole; Ketoconazole
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- 01 Sep 2018 Results published in the Clinical Pharmacology in Drug Development
- 20 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association